Explore the science of autoinflammatory RA

Interview with Dr. Dennis McGonagle, FRCPI PhD

Play Full Video Scroll through the Questions

Select a question to watch that segment

1 At what point in a patient's journey do you typically start to consider mechanisms outside those of classic adaptive immunity, such as IL-1 mediated pathways?

2 Which genetic (e.g., NLRP3, MEFV mutations) and lab tests do you find valuable in suspected autoinflammatory RA cases? Or is clinical presentation more than enough?

3 What are the key features that would make you prioritize a trial of an IL-1 blocking agent over changing to other biologic classes?

4 How might those features affect your choice between an IL-1 and IL-1 antagonists vs IL-1 alone?

5 How do you approach conversations with patients who feel frustrated or defeated after multiple treatment failures?

6 How might patient histories, pedigrees, or symptom timelines inform your treatment options beyond the usual RA treatment algorithm?

7 What aspects have you found challenging when educating patients about moving to an IL-1 targeted therapy?

8 What practical advice can you recommend to clinicians to help identify autoinflammatory-driven RA earlier in their patient’s disease course?

9 What are some common misconceptions among rheumatologists regarding refractory RA that you hope to address during your tour?

10 Do you think future guidelines will formally recognize autoinflammatory RA as a distinct subtype needing different treatment strategies?

Question 1 of 10

Gain new perspectives about IL-1 and its role in autoinflammatory RA

Want to hear more about autoinflammatory RA?

Watch Dr. Hugues Allard-Chamard explain the complexities of autoinflammatory RA, uncovering the roles of innate and adaptive immune systems and how genetic mutations can shape its manifestation.

Wondering whether any of your patients have autoinflammatory RA?

Join Dr. Hugues Allard-Chamard in an exploration of the clinical presentations of autoinflammatory RA, uncovering key distinctions between autoimmunity and autoinflammation and highlighting insights for diagnosis.

How does autoinflammatory RA treatment differ to what 
I am currently doing?

Watch Dr. Hugues Allard-Chamard explain treatment strategies for autoinflammatory RA, emphasizing targeted therapies aimed at innate immune system mediators such as IL-1, guiding clinicians in navigating treatment algorithms.

AIRA = autoinflammatory rheumatoid arthritis; IL-1 = interleukin-1; RA = rheumatoid arthritis